Overview

PD of VAY736 in Patients With Primary Sjögren's Syndrome

Status:
Completed
Trial end date:
2018-02-07
Target enrollment:
Participant gender:
Summary
This study was designed to evaluate the safety, tolerability, pharmacokinetics and therapeutic efficacy of a single intravenous infusion of VAY7346 monoclonal antibody in pSS patients
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals